
BioGaia AB (publ)
BIOGY
Updated: 24/09/2026, 11:39:35
BioGaia AB (publ) is a global enterprise dedicated to the development, marketing, and sale of probiotic products, all backed by documented health benefits. The company organizes its activities into three primary divisions: Pediatrics, Adult Health, and 'Other'. Within the Pediatric segment, BioGaia provides items such as liquid drops, oral rehydration solutions, and gut health tablets, alongside supplying probiotic cultures for integration into infant formula. The Adult Health segment offers both digestive health tablets and oral hygiene lozenges, as well as providing cultures that are incorporated into dairy products by its licensees. The 'Other' segment focuses on delivering packaging solutions. BioGaia's product portfolio addresses a wide array of health conditions, including infantile colic and digestive problems in children, acute and antibiotic-associated diarrhea, gingivitis, periodontal disease, general wellness, Helicobacter pylori infections (the bacterium causing gastric ulcers), and low bone density. All of the company's products are sold under the BioGaia brand. Founded in 1990, BioGaia AB (publ) is headquartered in Stockholm, Sweden.
No summaries found.
- Share price
- $12.45
- Market cap
- $1.26B
- Exchange
- OTC
- Currency
- USD
- CEO
- Theresa Agnew
- Employees
- 242
- IPO date
- 08/01/2021
- Beta
- 0.319
- Last dividend
- $0.00
- Day range
- $12.35 – $12.45
- 52-week range
- $9.64 – $12.45
- 1-day performance
- 0.00%
- 1-year performance
- 29.15%
- Current drawdown (1Y)
- 0.00%
- CIK
- 0001572957
- CUSIP
- 09072J102
- ISIN
- US09072J1025
- Created
- 07/12/2025, 03:00:01
- Last update
- 24/09/2026, 11:39:35
Track BioGaia AB (publ) with an AI analyst
See which prediction-market events move BIOGY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.